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background:  Measurement of B-type natiuretic peptide (BNP) or NT Pro-BNP has been advocated for cardiovascular disease (CVD) risk 
stratification. The purpose of this study is to assess the association between the presence of abnormal BNP/pro BNP with left ventricular hypertrophy 
(LVH) in asymptomatic normotensive subjects(sbjs).
methods:  We evaluated 2230 sbjs aged 23-80 years, who underwent screening for CVD risk using Early CVD Risk Score (ECVDRS), also known as 
Rasmussen Disease Score (DS). ECVDRS consists of 10 non-invasive tests including blood pressure (BP) at rest and post mild exercise (PME), left 
ventricular ultrasound, and BNP/Pro-BNP.
results: Among the 2230 asymptomatic sbjs, we analyzed 1309 with normal resting BP taking no anti-hypertensive medication. We created 
a logistic regression model to evaluate the factors associated with LVH (Normal Vs Abnormal) in this population with an 8.5% incidence of LVH 
(n=111). We used an initial non-parsimonious model including sbjs demographics, family history, physical activity, current smoking, BP PME, being 
on-treatment (Yes/No) and BNP/Pro-BNP (Normal Vs abnormal) to evaluate all these factors in such low risk population (n=1309). The final model 
was highly statistically significant (LR Chi-square = 103.41, df=5, p<0.0001) and the factors that remained significant other than age, sex, BMI and 
smoking was the BNP/ProBNP levels. The odds of having abnormal LVH findings for sbjs with abnormal BNP/ProBNP was 2.4 times that of sbjs of 
normal BNP/ProBNP controlling for abnormal BP PME rise and being treated for other CVD comorbidities. We also evaluated the model excluding 
current smokers from the analysis (n=1180) with LVH abnormality prevalence of 7.6% (n=90). It was highly significant (LR Chi-square = 81.12, df=4, 
p<0.0001) with odds of having abnormal LVH findings for sbjs with abnormal BNP/ProBNP equals 2.7 times that of sbjs of normal BNP/ProBNP 
controlling for the same factors.
conclusions:  Abnormal BNP/pro-BNP levels are highly predictive of echo-determined LVH. Measurement of ProBNP/BNP can serve as useful 
screening tool in asymptomsatic non-hypertensive sbjs to identify early cardiac disease likely to progress to morbid events.
